Author:
Wiendl Heinz,Kieseier Bernd
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Clinical Neurology
Reference10 articles.
1. Klotz, L., Meuth, S. G. & Wiendl, H. Immune mechanisms of new therapeutic strategies in multiple sclerosis—a focus on alemtuzumab. Clin. Immunol. 142, 25–30 (2012).
2. CAMMS223 Trial Investigators. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).
3. Cohen, J. A. et al. Alemtuzumab versus interferon β-1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).
4. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).
5. Jones, J. L. et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052–2061 (2009).
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献